Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESOLAC trial of levamisole in African children with nephrotic syndrome
PACTR202201750782433Phase 4Not yet recruiting
- Sponsor
- Caris Life Sciences
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Idiopathic nephrotic syndrome (INS) and nephrosis comparing Levamisole arm with Standard of care (2 arms). Primary endpoints: Number of relapses and Sustained remission period. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
levamisole
03
Conditions
Idiopathic nephrotic syndrome (INS)nephrosis
Beyond the preview
Go deeper on PACTR202201750782433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202201750782433.